%0 Journal Article
%A Zheng, Ziwen
%A Wieder, Thomas
%A Mauerer, Bernhard
%A Schäfer, Luisa
%A Kesselring, Rebecca
%A Braumüller, Heidi
%T T Cells in Colorectal Cancer: Unravelling the Function of Different T Cell Subsets in the Tumor Microenvironment.
%J International journal of molecular sciences
%V 24
%N 14
%@ 1422-0067
%C Basel
%I Molecular Diversity Preservation International
%M DKFZ-2023-01539
%P 11673
%D 2023
%X Therapeutic options for metastatic colorectal cancer (mCRC) are very limited, and the prognosis using combination therapy with a chemotherapeutic drug and a targeted agent, e.g., epidermal growth factor receptor or tyrosine kinase, remains poor. Therefore, mCRC is associated with a poor median overall survival (mOS) of only 25-30 months. Current immunotherapies with checkpoint inhibitor blockade (ICB) have led to a substantial change in the treatment of several cancers, such as melanoma and non-small cell lung cancer. In CRC, ICB has only limited effects, except in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors, which comprise about 15
%K NKT cells (Other)
%K T cell therapy (Other)
%K colorectal cancer (Other)
%K immune checkpoint blockade (Other)
%K immunoscore (Other)
%K tumor-infiltrating T cells (Other)
%K αβ T cells (Other)
%K γδ T cells (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37511431
%2 pmc:PMC10380781
%R 10.3390/ijms241411673
%U https://inrepo02.dkfz.de/record/277871